Abstract
The pharmaceutical industry, though global in nature, remains fragmented in practice. This paper explores current trends which will increase the internationalization of the industry: biotechnology, efficiency of licensing, standards of quality, and postmarketing activities. Harmonization and the future European registration system are, of course, crucial, and this discussion assumes their success.
Get full access to this article
View all access options for this article.